Dantari Debuts With $47 Million Series A To Advance Best-In-Class Targeted Medicines For Solid Tumors
Dantari Debuts With $47 Million Series A To Advance Best-In-Class Targeted Medicines For Solid Tumors
12/08/22, 10:02 AM
Location
thousand oaksMoney raised
$47 million
Industry
therapeutics
biotechnology
Round Type
series a
Investors
Alexandria Venture Investments, Corner Ventures, Westlake Village Bio Partners
Dantari, Inc. ("Dantari"), a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases, today announced its emergence from stealth mode with $47 million Series A financing. The Series A financing was led by Westlake Village BioPartners ("Westlake") and included participation from Corner Ventures, Alexandria Venture Investments, and Caltech. The Company also announced the appointment of Richard A
Company Info
Location
thousand oaks, california, united states
Additional Info
Dantari, Inc. is a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases. Dantari is advancing a pipeline of T-HDC (Targeted High-capacity Drug Conjugate) chemotherapeutic agents starting with DAN-222 and next-generation ADC therapeutics T-HDC technology originating from Caltech. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR), and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. Visit us at www.dantari.com to learn more.